T-cell deplete versus T-cell replete haploidentical hematopoietic stem cell transplantation for sickle cell disease: where are we?

References

• Johnson F, Look A, Gockerman J, et al. Bone marrow transplantation in a patient with sickle-cell anemia. N Engl J Med. 1984;311(12):780–783.
   PubMed Web of Science ®Google Scholar
• Vermylen C, Ninane J, Robles E, et al. Bone marrow transplantation in five children with sickle cell anaemia. Lancet. 1988;331(8600):P1427–P1428.
   Google Scholar
• Vermylen C, Cornu C. Bone marrow transplantation for sickle cell disease. The European experience. Am J Pediatr Hematol Oncol. 1994;16(1):18–21.
   PubMedGoogle Scholar
• Bernaudin F, Socie C, Kuentz M, et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood. 2007;110(7):2749–2756.
   PubMed Web of Science ®Google Scholar
• Ferster A, De Valck C, Azzi N, et al. Bone marrow transplantation for severe sickle cell anemia. Br J Haematol. 1992;80(1):102–105.
   PubMed Web of Science ®Google Scholar
• Walters M, Patience M, Leisenring W, et al. Bone marrow transplantation for sickle cell disease. N Engl J Med. 1996;335(6):369–376.
   PubMed Web of Science ®Google Scholar
• Gragert L, Eapen M, Williams E, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. Registry. N Engl J Med. 2014;371(4):339–348.
   PubMed Web of Science ®Google Scholar
• Bolanos-Meade J, Brodsky R. Blood and marrow transplantation for sickle cell disease: overcoming barriers to success. Curr Opin Oncol. 2009;21(2):158–161.
   PubMed Web of Science ®Google Scholar
• Joseph J, Abraham A, Fitzhugh C. When there is no match, the game is not over: alternative donor options for hematopoietic stem cell transplantation in sickle cell disease. Semin Hematol. 2018;55:94–101.
   PubMed Web of Science ®Google Scholar
• Shenoy S, Angelucci E, Arnold S, et al. Current results and future research priorities in late effects after hematopoietic stem cell transplantation for children with sickle cell disease and thalassemia: a consensus statement from the second pediatric blood and marrow transplant consortium international conference on late effects after pediatric hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2017;23:552–561.
   PubMed Web of Science ®Google Scholar
• King A, Shenoy S. Evidence-based focused review on the status of hematopoietic stem cell transplantation as treatment for sickle cell disease and thalassemia. Blood. 2014;123(20):3089–3094.
   PubMed Web of Science ®Google Scholar
• Kassim A, Sharma D. Hematopoietic stem cell transplantation for sickle cell disease: the changing landscape. Hematol Oncol Stem Cell Ther. 2017;10:259–266.
   PubMedGoogle Scholar
• Bolanos-Meade J, Fuchs E, Luznik L, et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 2012;120(22):4285–4291.
   PubMed Web of Science ®Google Scholar
• Al Malki M, Jones R, Ma Q, et al. Proceedings from the fourth haploidentical stem cell transplantation symposium (HAPLO2016), San Diego, California, December 1, 2016. Biol Blood Marrow Transplant. 2018;24:895–908.
   PubMedGoogle Scholar
• Aslam H, Yousuf S, Kassim A, et al. Hematopoietic stem cell transplantation for adult sickle cell disease in the era of universal donor availability. Bone Marrow Transplant. 2018;53:1390–1400.
   PubMedGoogle Scholar
• Booth C, Lawson S, Veys P. The current role of T cell depletion in paediatric stem cell transplantation. Br J Haematol. 2013;162:177–190.
   PubMed Web of Science ®Google Scholar
• Saad A, Lamb L. Ex vivo T-cell depletion in allogeneic hematopoietic stem cell transplant: past, present, and future. Bone Marrow Transplant. 2017;52:1241–1248.
   PubMedGoogle Scholar
• Ho V, Soiffer R. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood. 2001;98(12):3192–3204.
   PubMed Web of Science ®Google Scholar
• Aversa F. Setting the standard in T-cell-depleted haploidentical transplantation and beyond. Best Pract Res Clin Haematol. 2011;24:325–329.
   PubMed Web of Science ®Google Scholar
• Bashey A, Solomon S. T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor. Bone Marrow Transplant. 2014;49:999–1008.
   PubMedGoogle Scholar
• Luznik L, O’Donnell P, Fuchs E. Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical BMT. Semin Oncol. 2012;39(6):1–14.
   PubMed Web of Science ®Google Scholar
• Luznik L, O’Donnell P, Symons H, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641–650.
   PubMed Web of Science ®Google Scholar
• Brodsky R, Luznik L, Bolanos-Meade J, et al. Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases. Bone Marrow Transplant. 2008;42(8):523–527.
   PubMed Web of Science ®Google Scholar
• Dallas M, Triplett B, Shook D, et al. Long-term outcome and evaluation of organ function in pediatric patients undergoing haploidentical and matched related hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2013;19:820–830.
   PubMed Web of Science ®Google Scholar
• Platt O, Brambilla D, Rosse W, et al. Mortality in sickle cell disease – life expectancy and risk factors for early death. N Engl J Med. 1994;330:1639–1644.
   PubMed Web of Science ®Google Scholar
• Rees D, Williams T, Gladwin M. Sickle-cell disease. Lancet. 2010;376:2018–2031.
   PubMed Web of Science ®Google Scholar
• Quinn C, Rogers Z, McCavit T, et al. Improved survival of children and adolescents with sickle cell disease. Blood. 2010;115(17):3447–3452.
   PubMed Web of Science ®Google Scholar
• Piel F, Steinberg M. Sickle cell disease. N Engl J Med. 2017;376(16):1561–1573.
   PubMed Web of Science ®Google Scholar
• Hassell K. Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010;38(4):S512–S521.
   PubMed Web of Science ®Google Scholar
• CDC website sickle cell disease. https://www.cdc.gov/ncbddd/sicklecell/data.html. Accessed on Jun 14, 2019.
   Google Scholar
• Weatherall D. The inherited diseases of hemoglobin are an emerging global health burden. Blood. 2010;115(22):4331–4336.
   PubMed Web of Science ®Google Scholar
• Hebbel R. Ischemia-reperfusion injury in sickle cell anemia: relationship to acute chest syndrome, endothelial dysfunction, arterial vasculopathy, and inflammatory pain. Hematol Oncol Clin North Am. 2014;28(2):181–198.
   PubMed Web of Science ®Google Scholar
• Fitzhugh C, Walters M. The case for HLA-identical sibling hematopoietic stem cell transplantation in children with symptomatic sickle cell anemia. Blood Adv. 2017;1(26):2563–2567.
   PubMed Web of Science ®Google Scholar
• Schatz J, Brown R, Pascual J, et al. Poor school and cognitive functioning with silent cerebral infarcts and sickle cell disease. Neurology. 2001;56(8):1109–1111.
   PubMed Web of Science ®Google Scholar
• Yawn B, Buchanan G, Afenyi-Annan A, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312(10):1033–1048.
   PubMed Web of Science ®Google Scholar
• Charache S, Terrin M, Moore R, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med. 1995;332(20):1317–1322.
   PubMed Web of Science ®Google Scholar
• Platt O. Hydroxyurea for the treatment of sickle cell anemia. N Engl J Med. 2008;358(13):1362–1369.
   PubMed Web of Science ®Google Scholar
• Wong T, Brandow A, Lim W, et al. Update on the use of hydroxyurea therapy in sickle cell disease. Blood. 2014;124(26):3850–3857.
   PubMed Web of Science ®Google Scholar
• Fitzhugh C, Hsieh M, Allen D, et al. Hydroxyurea-increased fetal hemoglobin is associated with less organ damage and longer survival in adults with sickle cell anemia. PLoS One. 2015;10(11):e0141706.
   PubMed Web of Science ®Google Scholar
• Ataga K, Kutlar A, Kanter J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017;376:429–439.
   PubMed Web of Science ®Google Scholar
• Niihara Y, Miller S, Kanter J, et al. A phase 3 trial of L-Glutamine in sickle cell disease. N Engl J Med. 2018;379:226–235.
   PubMed Web of Science ®Google Scholar
• DeBaun M, Gordon M, McKinstry R, et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med. 2014;371:699–710.
   PubMed Web of Science ®Google Scholar
• DeBaun M, Quirolo K. Chronic transfusion therapy for stroke in sickle cell disease. J Clin Apher. 2017;32(5):368–370.
   PubMed Web of Science ®Google Scholar
• Kassim A, Pruthi S, Day M, et al. Silent cerebral infarcts and cerebral aneurysms are prevalent in adults with sickle cell anemia. Blood. 2016;127(16):2038–2040.
   PubMed Web of Science ®Google Scholar
• Jordan L, Kassim A, Donahue M, et al. Silent infarct is a risk factor for infarct recurrence in adults with sickle cell anemia. Neurology. 2018;91(8):e781–e784.
   PubMed Web of Science ®Google Scholar
• Ware R, Davis B, Schultz W, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia – TCD with Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2016;387(10019):661–670.
   PubMed Web of Science ®Google Scholar
• Hulbet M, McKinstry R, Lacey J, et al. Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease. Blood. 2011;117(3):772–779.
   PubMed Web of Science ®Google Scholar
• Porter J, Garbowski M. Consequences and management of iron overload in sickle cell disease. Hematology Am Soc Hematol Educ Program. 2013;2013:447–456.
   PubMedGoogle Scholar
• Hoban M, Orkin S, Bauer D. Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease. Blood. 2016;127:839–848.
   PubMed Web of Science ®Google Scholar
• Ribeil, Ribeil J-A, Hacein-Bey-Abina S, et al. Gene therapy in a patient with sickle cell disease. N Engl J Med. 2017;376:848–855.
   PubMed Web of Science ®Google Scholar
• Hsieh M, Kang E, Fitzhugh C, et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med. 2009;361(24):2309–2317.
   PubMed Web of Science ®Google Scholar
• Eggleston B, Patience S, Edwards T, et al. Effect of myeloablative bone marrow transplantation on growth in children with sickle cell anaemia: results of the multicenter study of hematopoietic cell transplantation for sickle cell anaemia. Br J Haematol. 2006;136:673–676.
   Web of Science ®Google Scholar
• Brachet C, Heinrichs C, Tenoutasse S, et al. Children with sickle cell disease: growth and gonadal function after hematopoietic stem cell transplantation. J Pediatr Hematol Oncol. 2007;29(7):445–450.
   PubMed Web of Science ®Google Scholar
• Gaziev J, Isgro A, Mozzi A, et al. New insights into the pharmacokinetics of intravenous busulfan in children with sickle cell anemia undergoing bone marrow transplantation. Pediatr Blood Cancer. 2015;62:680–686.
   PubMed Web of Science ®Google Scholar
• DeBaun M, Clayton E. Primum non nocere: the case against transplant for children with sickle cell anemia without progressive end-organ disease. Blood Adv. 2017;1(26):2568–2571.
   PubMed Web of Science ®Google Scholar
• Fitzhugh C, Abraham A, Tisdale J, et al. Hematopoietic stem cell transplantation for patients with sickle cell disease: progress and future directions. Hematol Oncol Clin North Am. 2014;28(6):1171–1185.
   PubMed Web of Science ®Google Scholar
• Krishnamurti L, Abel S, Maiers M, et al. Availability of unrelated donors for hematopoietic stem cell transplantation for hemoglobinopathies. Bone Marrow Transplant. 2003;31(7):547–550.
   PubMed Web of Science ®Google Scholar
• Abraham A, Hsieh M, Eapen M, et al. Relationship between mixed donor-recipient chimerism and disease recurrence after hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2017;23(12):2178–2183.
   PubMed Web of Science ®Google Scholar
• Oh H, Loberiza F, Zhang M-J, et al. Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. Blood. 2005;105:1408–1416.
   PubMed Web of Science ®Google Scholar
• Eckrich M, Ahn K, Champlin R, et al. Effect of race on outcomes after allogeneic hematopoietic cell transplantation for severe aplastic anemia. Am J Hematol. 2013;89(2):125–129.
   PubMed Web of Science ®Google Scholar
• Shenoy S, Eapen M, Panepinto J, et al. A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. Blood. 2016;128(21):2561–2567.
   PubMed Web of Science ®Google Scholar
• Abraham A, Cluster A, Jacobsohn D, et al. Unrelated umbilical cord blood transplantation for sickle cell disease following reduced-intensity conditioning: results of a phase I trial. Biol Blood Marrow Transplant. 2017;23(9):1587–1592.
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Bareford D. A survey on patient perception of reduced-intensity transplantation in adults with sickle cell disease. Bone Marrow Transplant. 2007;39:447–451.
   PubMed Web of Science ®Google Scholar
• Powles R, Kay H, Clink H, et al. Mismatched family donors for bone-marrow transplantation as treatment for acute leukemia. Lancet. 1983;1(8325):612–615.
   PubMed Web of Science ®Google Scholar
• Beatty P, Clift R, Mickelson E, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med. 1985;313(13):765–771.
   PubMed Web of Science ®Google Scholar
• Anasetti C, Amos D, Beatty P, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med. 1989;320:197–204.
   PubMed Web of Science ®Google Scholar
• Szydlo R, Goldman J, Klein J, et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol. 1997;15(5):1767–1777.
   PubMed Web of Science ®Google Scholar
• Bertaina A, Pitisci A, Sinibaldi M, et al. T cell-depleted and T cell-replete HLA-Haploidentical stem cell transplantation for non-malignant disorders. Curr Hematol Malig Rep. 2017;12(1):68–78.
   PubMed Web of Science ®Google Scholar
• Aversa F, Tabilio A, Terenzi A, et al. Successful engraftment of T-cell depleted haploidentical “three-loci” incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood. 1994;84(11):3948–3955.
   PubMed Web of Science ®Google Scholar
• Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-Cell depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998;339:1186–1193.
   PubMed Web of Science ®Google Scholar
• Ruggeri A, Eapen M, Scaravadou A, et al. Umbilical cord blood transplantation for children with thalassemia and sickle cell disease. Biol Blood Marrow Transplant. 2011;17(9):1375–1382.
   PubMed Web of Science ®Google Scholar
• Kamani N, Walters M, Carter S, et al. Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the blood and marrow transplant clinical trials network (BMT CTN). Biol Blood Marrow Transplant. 2012;18(8):1265–1272.
   PubMed Web of Science ®Google Scholar
• Munoz J, Shah N, Rezvani K, et al. Concise review: umbilical cord blood transplantation: past, present, and future. Stem Cells Transl Med. 2014;3(12):1435–1443.
   PubMed Web of Science ®Google Scholar
• Bertaina A, Merli P, Rutella S, et al. HLA-haploidentical stem cell transplantation after removal of alpha/beta+ T and B cells in children with nonmalignant disorders. Blood. 2014;124(5):822–826.
   PubMed Web of Science ®Google Scholar
• Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood. 2011;117(4):3921–3928.
   PubMedGoogle Scholar
• Martelli M, Di Ianni M, Ruggeri L, et al. HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. Blood. 2014;124(4):638–644.
   PubMed Web of Science ®Google Scholar
• Abikoff C, Talano J, Keever-Taylor C, et al. Familial Haploidentical (FHI) T-Cell Depleted (TCD) with T-Cell Addback Stem Cell Transplantation for patients with high-risk Sickle Cell Disease (SCD) (IND 14359). Blood. 2014;124(21):2582.
   Google Scholar
• Cairo M, Talano J, Moore T, et al. Familial Haploidentical (FHI) allogeneic stem cell transplantation utilizing CD34 Enrichment and T Cell addback in children, adolescents, & adults with high-risk sickle cell disease. Rapid engraftment, low incidence of agvhd, and sustained donor chimerism. Biol Blood Marrow Transplant. 2016;22(3):S367–S368.
   Google Scholar
• Kanakry C, Fuchs E, Luznik L. Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol. 2016;13(1):10–24.
   PubMed Web of Science ®Google Scholar
• Luznik L, Jalla S, Engstrom L, et al. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001;98(12):3456–3464.
   PubMed Web of Science ®Google Scholar
• O’Donnell P, Luznik L, Jones R, et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002;8(7):377–386.
   PubMed Web of Science ®Google Scholar
• Kanakry C, Ganguly S, Zahurak K, et al. Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med. 2013;5(211):211ra157.
   PubMed Web of Science ®Google Scholar
• Ganguly S, Ross D, Panoskaltsis-Mortari A, et al. Donor CD4+ FOXP3+ regulatory T cells are necessary for posttransplantation cyclophosphamide mediated protection against GVHD in mice. Blood. 2014;124(13):2131–2141.
   PubMed Web of Science ®Google Scholar
• Foell J, Pfirstinger B, Rehe K, et al. Haploidentical stem cell transplantation with CD3+-/CD19+- depleted peripheral stem cells for patients with advanced stage sickle cell disease and no alternative donor: results of a pilot study. Bone Marrow Transplant. 2017;52(6):938–940.
   PubMed Web of Science ®Google Scholar
• Sjoo F, Hassan Z, Abedi-Valugerdi M, et al. Myeloablative and immunosuppressive properties of treosulfan in mice. Exp Hematol. 2006;34(1):115–121.
   PubMed Web of Science ®Google Scholar
• Gilman A, Eckrich M, Epstein S, et al. Alternative donor hematopoietic stem cell transplantation for sickle cell disease. Blood Adv. 2017;1(16):1215–1223.
   PubMed Web of Science ®Google Scholar
• Gaziev J, Isgro A, Sodani P, et al. Haploidentical HSCT for hemoglobinopathies: improved outcomes with TCR alpha/beta+/CD19+- depleted grafts. Blood Adv. 2017;2(3):263–270.
   Web of Science ®Google Scholar
• Gladstone D, Zachary A, Fuchs E, et al. Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies. Biol Blood Marrow Transplant. 2013;19(4):647–652.
   PubMed Web of Science ®Google Scholar
• Ciurea S, de Lima M, Cano P, et al. High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation. 2009;88(8):1019–1024.
   PubMed Web of Science ®Google Scholar
• Fitzhugh C, Hsieh M, Taylor T, et al. Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT. Blood Adv. 2017;1(11):652–661.
   PubMed Web of Science ®Google Scholar
• Saraf S, Oh A, Patel P, et al. Haploidentical peripheral blood stem cell transplantation demonstrates stable engraftment in adults with sickle cell disease. Biol Blood Marrow Transplant. 2018;24:1754–1770.
   PubMedGoogle Scholar
• Narimatsu H, Wake A, Miura Y, et al. Successful engraftment in crossmatch-positive HLA-mismatched peripheral blood stem cell transplantation after depletion of antidonor cytotoxic HLA antibodies with rituximab and donor platelet infusions. Bone Marrow Transplant. 2005;36:555–556.
   PubMed Web of Science ®Google Scholar
• De la Fuente J, Dhedin N, Koyama T, et al. Haploidentical bone marrow transplant with post-transplant cyclophosphamide plus thiotepa improves donor engraftment in patients with sickle cell anemia: results of an international learning collaborative. Biol Blood Marrow Transplant. 2018;25(6):1197–1209.
   Google Scholar
• ElAlfy M, Adly A, Ebeid S, et al. Immunological role of CD4+CD28null T lymphocytes, natural killer cells, and interferon-gamma in pediatric patients with sickle cell disease: relation to disease severity and response to therapy. Immunol Res. 2018;66:480–490.
   PubMed Web of Science ®Google Scholar
• Ayello J, Chu Y, Keever-Taylor C, et al. Familial Haploidentical (FHI) Allogeneic Stem Cell Transplantation (AlloSCT) Utilizing CD34 enrichment and PB MNC addback in children and adolescents with high risk Sickle Cell Disease (SCD): rapid engraftment, immune cell reconstitution, and sustained donor chimerism (IND 14539). Blood. 2016;128:1245.
   Google Scholar
• Talano J, Moore T, Keever-Taylor C, et al. Promising results at 1 year follow-up following Familial Haploidentical (FHI) T-Cell Depleted (TCD) with CD34 Enrichment and T-Cell (CD3) addback allogeneic stem cell transplantation in patients with high-risk Sickle Cell Disease (SCD) (IND 14359) [abstract]. Blood. 2017 Dec 7;130(1):4602. Atlanta, GA.
   Google Scholar
• Patel D, Dhedin N, Chen H, et al. Delayed immune reconstitution and increased viral infections following haploidentical BMT with post-transplant cyclophosphamide for sickle cell disease: results of a haploidentical transplant consortium for hemoglobinopathies (ICHH). Biol Blood Marrow Transplant. 2019;25(3):S39–S40.
   Google Scholar
• Marzollo A, Calore E, Tumino M, et al. Treosulfan-based conditioning regimen in sibling and alternative donor hematopoietic stem cell transplantation for children with sickle cell disease. Mediterr J Hematol Infect Dis. 2017;9:1–9.
   Web of Science ®Google Scholar
• Wiebking V, Hutker S, Schmid I, et al. Reduced toxicity, myeloablative HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for sickle cell disease. Ann Hematol. 2017;96(8):1373–1377.
   PubMed Web of Science ®Google Scholar
• Pawlowska A, Cheng J, Karras N, et al. HLA haploidentical stem cell transplant with pretransplant immunosuppression for patients with sickle cell disease. Biol Blood Marrow Transplant. 2018;24:185–199.
   PubMed Web of Science ®Google Scholar
• Angelucci E, Matthes-Martin S, Baronciani D, et al. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica. 2014;99:811–820.
   PubMed Web of Science ®Google Scholar
• Ciurea S, Champlin R. Donor selection in T cell-replete haploidentical hematopoietic stem cell transplantation: knowns, unknowns, and controversies. Biol Blood Marrow Transplant. 2013;19:180–184.
   PubMed Web of Science ®Google Scholar
• Braun N, Faul C, Wernet D, et al. Successful transplantation of highly selected CD34+ peripheral blood stem cells in a HLA-sensitized patient treated with immunoadsorption onto protein A. Transplantation. 2000;69:1742–1744.
   PubMed Web of Science ®Google Scholar